An active multicenter early phase II study is currently investigating the effectiveness of local tumor ablation (radiofrequency ablation or stereotactic body radiation therapy) in combination with durvalumab (Anti-PD-1) and tremelimumab (anti-CTLA-4) in ICI naïve patients with unresectable colorectal liver metastases (NCT03101475). Here, CTLA4 is linked to neoplasm.